Vanessa Carle Sells 2,567 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) Stock

Lexaria Bioscience Corp. (NASDAQ:LEXX) insider Vanessa Carle sold 2,567 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $4.00, for a total transaction of $10,268.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Lexaria Bioscience Trading Down 2.7 %

LEXX opened at $3.98 on Friday. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.90. Lexaria Bioscience Corp. has a 1 year low of $0.80 and a 1 year high of $6.85.

Institutional Trading of Lexaria Bioscience

An institutional investor recently bought a new position in Lexaria Bioscience stock. Cowen AND Company LLC bought a new stake in Lexaria Bioscience Corp. (NASDAQ:LEXX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 256,327 shares of the company’s stock, valued at approximately $320,000. Cowen AND Company LLC owned about 2.46% of Lexaria Bioscience as of its most recent SEC filing. 13.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Lexaria Bioscience in a research note on Thursday, July 18th.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.